Heinz Philipp Laubli

This paper explores using anti-TSHR autoantibodies to create bispecific antibodies and CAR T cells for treating poorly differentiated thyroid cancer, showing potent in vitro and in vivo activity.

Desialylation enhances bispecific T cell engager responses by relieving a sialoglycan-dependent restraint in human T cells.

This study shows that local glycan engineering using AAV-delivered sialidases reduces tumor growth and enhances systemic antitumor immunity through improved cross-presentation and dendritic cell activation.

This study profiles tumor-reactive T cell dynamics during TIL therapy in metastatic melanoma, identifying factors associated with response and resistance.

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

This study screens TCR-based CAR designs to improve anti-tumor efficacy by incorporating CD28 and CD27 costimulatory domains, showing enhanced performance in mouse tumor models.

This study develops a fully human CAR-T cell therapy targeting the STn antigen, showing activity in preclinical models of gastro-intestinal and gynecological cancers.

This study compares viral and non-viral methods for CAR T cell engineering, finding that non-viral SB transposition alters T cell activation and co-inhibition markers, with CAR design and donor type influencing outcomes.